Satraplatin is a platinum chemotherapy compound that can be administered orally. It appears to have minimal risk of neuropathy or kidney injury. Phase III studies have demonstrated that Satraplatin is more active that prednisone alone for patients with advanced HRPC who have already failed existing standard therapies. Satraplatin is pending approval by the FDA. It is currently available only within a study program. CORT is pleased to offer access to Satraplatin through the Expanded Access Study. All patients who qualify will receive Satraplatin. The risks of Satraplatin include nausea, vomiting, fatigue, diarrhea, and low blood counts.
For more information on our research studies, visit www.CORTPA.com, or speak with a Study Coordinator at 972-566-5588.
Tags: androgen independent prostate cancer, Expanded Access Study, hormone refractory prostate cancer, Prostate Cancer, Satraplatin
